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ABSTRACT
Objective To explore the acceptability of different 
bisphosphonate regimens for the treatment of osteoporosis 
among patients, clinicians and managers, payers and 
academics.
Design A systematic review of primary qualitative studies. 
Seven databases were searched from inception to July 
2019. Screening, data extraction and quality assessment 
of full- articles selected for inclusion were performed 
independently by two authors. A framework synthesis 
was applied to extracted data based on the theoretical 
framework of acceptability (TFA). The TFA includes seven 
domains relating to sense- making, emotions, opportunity 
costs, burden, perceived effectiveness, ethicality and self- 
efficacy. Confidence in synthesis findings was assessed.
Setting Any developed country healthcare setting.
Participants Patients, healthcare professionals, 
managers, payers and academics.
Intervention Experiences and views of oral and 
intravenous bisphosphonates.
Results Twenty- five studies were included, mostly 
describing perceptions of oral bisphosphonates. We 
identified, with high confidence, how patients and 
healthcare professionals make sense (coherence) of 
bisphosphonates by balancing perceptions of need against 
concerns, how uncertainty prevails about bisphosphonate 
perceived effectiveness and a number of individual and 
service factors that have potential to increase self- efficacy 
in recommending and adhering to bisphosphonates. We 
identified, with moderate confidence, that bisphosphonate 
taking induces concern, but has the potential to engender 
reassurance, and that both side effects and special 
instructions for taking oral bisphosphonates can result 
in treatment burden. Finally, we identified with low 
confidence that multimorbidity plays a role in people’s 
perception of bisphosphonate acceptability.
Conclusion By using the lens of acceptability, our findings 
demonstrate with high confidence that a theoretically 
informed, whole- system approach is necessary to both 
understand and improve adherence. Clinicians and 
patients need supporting to understand the need for 
bisphosphonates, and clinicians need to clarify to patients 
what constitutes bisphosphonate treatment success. 
Further research is needed to explore perspectives of 
male patients and those with multimorbidity receiving 
bisphosphonates, and patients receiving intravenous 
treatment.
PROSPERO registration number CRD42019143526.
INTRODUCTION/BACKGROUND
Osteoporosis is a disease that is character-
ised by skeletal fragility and changes in bone 
microarchitecture resulting in increased 
risk of fractures with no or low trauma.1 The 
management and care of people with low 
trauma or fragility fractures results in consid-
erable societal economic burden, annual cost 
in the UK alone is £4.4 billion.2 Furthermore, 
the personal impact of fragility fractures 
is considerable, with potential deleterious 
effects on physical and psychological health, 
ability to live independently and increased 
risk of death. Many of these fractures are 
potentially preventable with appropriate cost 
effective and clinically effective drug treat-
ments such as bisphosphonates, the main-
stay of osteoporosis treatment. However, the 
success of treatment depends on patients 
initiating (starting), executing (or imple-
menting—taking correctly) and persisting 
(continuing) medication; collectively these 
Strengths and limitations of this study
 ► Comprehensive search strategy.
 ► Robust framework synthesis underpinned by theory.
 ► Inclusion of clinician and manager views in addition 
to patient perspectives.
 ► Use of Grades of Recommendation, Assessment, 
Development, and Evaluation Confidence in the 
Evidence from Qualitative Reviews to give confi-
dence in findings.
 ► Qualitative studies reviewed for inclusion were 
frequently not specific about the anti- osteoporosis 
drugs participants were taking, meaning we may 
have missed papers or over- interpreted findings.
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processes are described as adherence. Adherence with 
osteoporosis medications is notoriously poor and reported 
to be poorer than other disease areas. Oral bisphospho-
nate persistence rates at 1 year are commonly estimated 
between 16% and 60%.3 Worldwide, many people who 
would benefit from osteoporosis drugs are not receiving 
them, and this treatment gap has been described as an 
‘osteoporosis crisis’.4 The treatment gap is compounded 
by poor adherence which results in potentially prevent-
able fragility fractures with their associated burden for 
patients and their carers, difficulties in professional–
patient relationships, and wasted healthcare resources.5
There are a number of different bisphosphonates, 
some are administered orally, others intravenously. A 
variety of regimes in terms of dose frequency also exists. 
Alendronic acid, an oral once- weekly bisphosphonate, is 
considered first- line and most commonly used.6 Bisphos-
phonates work to reduce fracture risk. A recent network 
meta- analysis demonstrated that bisphosphonate treat-
ment reduces the risk of fragility fracture (depending 
on site) by 33%–54%.7 Oesophageal or gastrointestinal 
related side effects are the most common adverse effects 
of oral bisphosphonate use. To counter these, patients 
taking oral bisphosphonates are required to remain 
upright and fast for half an hour after ingestion. Rare 
side effects of bisphosphonates include osteonecrosis of 
the jaw and atypical femur fractures, both of which have 
received significant media attention. Such media reports 
are temporally related to declining bisphosphonate use.7 
Due to the gastrointestinal side effects and special instruc-
tions for taking oral treatment, it has been suggested 
that alternative bisphosphonate regimens, for example, 
annual intravenous zoledronic acid, may promote long- 
term adherence.8–11 Studies to date which have examined 
patient preferences for osteoporosis treatment, suggest 
that patients prefer injections given less frequently12–14; 
however, research in other chronic diseases shows that 
although adherence is improved with less frequent medi-
cations, that patients prefer oral to injection treatment.15 
In osteoporosis, the majority of studies that explore 
patient preferences employ quantitative methods, for 
example, discrete choice experiments, where patients 
are asked to choose between hypothetical treatments in 
regards to various attributes (eg, efficacy, side effects, 
route and frequency of administration).13 Such studies 
cannot provide comprehensive insight into patient views, 
experiences or the explanations for these preferences.
In order to fully understand the osteoporosis treatment 
gap, and ultimately improve adherence, it is important 
to understand perspectives of all relevant stakeholders: 
patients, healthcare professionals (HCPs), managers, 
payors and academics.16 17 This can be achieved using 
the lens of ‘acceptability’, defined as ‘a multi- faceted 
construct that reflects the extent to which people deliv-
ering, or, receiving a healthcare intervention consider 
it to be appropriate, based on anticipated or experi-
enced cognitive and emotional responses to the inter-
vention’.18 19 In the context of a research programme 
designed to determine the research agenda for opti-
mising bisphosphonate treatment, the primary aim of 
this systematic review is to explore the acceptability of 
different bisphosphonates regimens among patients, and 
clinicians and managers.
METHODS
We conducted a systematic review and framework 
synthesis of qualitative studies exploring patient and 
clinician views and experiences of bisphosphonates. 
The conduct and reporting of this review followed the 
Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses (PRISMA) guidelines (see online supple-
mental file 1 for PRISMA checklist).
Eligibility
To be eligible for inclusion, studies needed to report 
on patients’, clinicians’, academics’ and/or manager/
payers’ experiences and preferences regarding bisphos-
phonate regimes for adults (≥18 years) with osteoporosis. 
Bisphosphonates needed to be mentioned by name, 
or there needed to be sufficient information that was 
specific to bisphosphonate (eg, reference to the special 
instructions for use of oral bisphosphonates), to deduce 
that study findings related to bisphosphonates, as agreed 
by two clinically experienced authors independently. 
Papers describing experiences of osteoporosis more 
generally were included if there were findings relating to 
bisphosphonate treatment in the study abstract. Studies 
were only included if they were qualitative in design, or 
mixed methods with a qualitative component, relevant 
to a developed country setting and written in English 
language. Studies were excluded that involved paedi-
atric patients; patients and clinicians receiving/recom-
mending other treatments for osteoporosis; and studies 
in which bisphosphonates were being used for other indi-
cations (eg, malignancy or Paget’s disease).
Search methods
Systematic searches were conducted in seven bibliographic 
databases (MEDLINE, EMBASE, AMED, CINAHLPlus, 
PsycINFO, ASSIA, and Web of Science (Social Science 
Citation Index and Conference Proceedings Citation 
Index- Social Science and Humanities)) from inception 
to 15 July 2019. The search strategy used database subject 
headings and text word searching in title, abstract or 
keywords, combining terms for: (1) bisphosphonates; 
(2) experiences and preferences; and (3) qualitative 
research, based on DeJean et al’s search filter (see online 
supplemental file 2 for full MEDLINE search strategy).19 
Search terms were adapted as appropriate for each data-
base platform.
In addition, grey literature was searched (DART Europe, 
Open Grey and National Digital Library of Theses and 
Dissertations); the reference lists of all included studies 
and relevant systematic reviews identified were checked 
and key studies were citation tracked.
3Paskins Z, et al. BMJ Open 2020;10:e040634. doi:10.1136/bmjopen-2020-040634
Open access
Study selection
Two- stage screening of articles against eligibility criteria 
was undertaken. First, titles and abstracts were screened, 
then full texts. At both stages screening was conducted 
by sets of two reviewers independently (NC, EC, ZP) and 
articles were excluded by agreement. Disagreements 
were resolved through discussion or by third reviewer 
adjudication.
Data extraction
For each paper data extraction was completed inde-
pendently by two researchers (ZP and JW or EC and FM). 
Key findings from the results sections of papers relating 
to bisphosphonates were extracted; a ‘key finding’ was 
defined as any sentence or statement relating to views 
or experiences of bisphosphonates from the results 
section of the paper or abstract. Wherever possible, 
the key finding was extracted as written by the author, 
with minimal edits only for clarification, description of 
context or for consistency across papers. For each paper, 
two authors extracted key findings independently, and 
subsequently agreed a final list of key findings for each 
paper. Data were also extracted on participant numbers 
and demographics, data collection technique, setting and 
country. Additionally, if available for patients, informa-
tion was extracted on their bisphosphonate use including 
type of drug and current status (adherent, non- adherent, 
decliner).
Quality appraisal
The quality of each study was assessed using the Critical 
Appraisal Skills Programme (CASP) qualitative tool. This 
tool consists of 10 items split into 3 sections (qualita-
tive suitability, data analysis and overall quality) (online 
supplemental file 2). The first two sections consist of 
items related to qualitative suitability and data analysis, 
which were evaluated as ‘yes’, ‘no’, ‘unclear’ or ‘partial’. 
The final question was an assessment based on the overall 
quality of the paper; this was informed by response to the 
previous items (indicating methodological quality) and 
by the relevance of the study to the review objectives and 
was rated as ‘high’, ‘moderate’ or ‘low’. All papers were 
quality appraised by two researchers independently (FM, 
SB, JW). Disagreements were resolved through discussion 
with a fourth reviewer (ZP).
Synthesis
We used a framework synthesis approach informed by the 
‘best fit’ model described by Carroll et al.20 The ‘best fit’ 
method offered a means to test, reinforce and build on 
an existing published model, conceived for a different 
but relevant purpose. This approach was chosen as a 
published theory was identified from the literature that 
conceptualised acceptability—the theoretical frame-
work of acceptability (TFA).18 The TFA is a relatively new 
framework which was developed to inform the under-
standing of acceptability of complex interventions, and 
consists of seven constructs: affective attitudes—the 
emotions elicited by an intervention; intervention coher-
ence—the extent to which an intervention makes sense; 
perceived effectiveness—the perceived extent to which 
intervention will achieve purpose; burden—the amount 
of effort required to participate in an intervention; self- 
efficacy—individual’s confidence that they can perform 
the behaviour(s) required to participate in the inter-
vention; opportunity- costs—the extent to which bene-
fits, profits, or values must be given up to engage in an 
intervention; and ethicality—the extent to which an 
intervention has a good fit with an individual’s values. 
The framework also incorporates temporal perspectives 
on anticipated and experienced acceptability at three time 
points before (prospective), during (experienced) and 
after (retrospective) experience of an intervention.
The TFA has not previously been used to evaluate 
drug acceptability. We anticipated the seven constructs 
of the TFA would be relevant to engagement with drug 
treatment; for example, burden could relate to treat-
ment burden associated with administrating the drug or 
side effects. However, one aspect which did not appear 
to be explicitly conceptualised within the framework 
was patient beliefs about medicines. Studies across a 
range of long term conditions, healthcare systems and 
cultures have consistently shown that engagement with 
treatment is influenced by patients’ personal evaluation 
of the medicine in question.21 Particularly important is 
how they judge their personal need for treatment relative 
to their concerns about it. For this reason, we therefore 
included the Necessity Concerns Framework (NCF),21 to 
further explore the TFA domain relating to intervention 
coherence.
The first author initially conducted inductive open 
coding on the data extracted, before mapping the codes 
to a draft framework derived from a priori themes (the 
domains of the TFA). Authors then met to first discuss 
the themes and compare findings for each study and 
the ‘fit’ to the draft framework. A preliminary synthesis 
was achieved using tabulation of studies, organising the 
studies into groups relating to temporal perspectives and 
research question, and exploring relationships between 
studies and between groups.
A final coding framework was agreed at a second 
meeting of authors. A second author (FM) recoded the 
original key findings, where necessary, to the new frame-
work to ensure all findings were represented. Finally, 
relationships between themes and TFA and NCF domains 
were explored by further group discussion. We used the 
Grades of Recommendation, Assessment, Development, 
and Evaluation Confidence in the Evidence from Qualita-
tive Reviews (GRADE- CERQual) approach to determine 
confidence in our synthesised findings.22
Patient and public involvement
Members of the Nottingham National, Royal Osteopo-
rosis Society Support Group were involved in a series of 
meetings to discuss the design of the overarching research 
programme in which this study sits, and confirmed that 
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understanding acceptability of bisphosphonates from 
a range of perspectives was important. Patient were not 
directly involved in the conduct of this study.
RESULTS
The literature search identified 2040 unique articles, of 
which 25 met eligibility criteria (figure 1), a summary of 
the studies is shown in table 1.
The included studies were categorised into three 
groups: perceptions of osteoporosis generally23–29; health-
care service delivery issues unrelated to osteoporosis 
(de- prescribing30 and inter- professional communication 
in primary care31) and studies specific to osteoporosis 
treatments. The latter group was further subdivided into: 
those examining treatment barriers16 32–36; adherence37–39; 
decision- making40–44; or bisphosphonate- related side 
effects.45 46 Only one study examining adherence and 
one examining decision making had research questions 
which specifically related to bisphosphonates.38 43
The majority (23) of studies were conducted in North 
America or Europe. Eighteen studies explored patient 
views,16 23–27 33 35 37–46 of which eight included men, and 
one study recruited patients taking anti- osteoporosis 
drugs for glucocorticoid- induced osteoporosis.36 Twelve 
studies explored HCPs’ views,16 28–32 34–36 39 42 43 and two 
studies interviewed managers.16 34 No studies included 
academic or payor participants. Of the 18 studies that 
included patients, 10 studies described how many of the 
patients were on anti- osteoporotic medication, however, 
only two reported the specific type of medication. Only 
one study reporting patient experience of receiving intra-
venous bisphosphonate.27
The findings related to quality appraisal are summarised 
in table 2. The most common limitations of the included 
studies were lack of description of author reflexivity, 
lack of depth of analysis, use of normative statements 
and relatively small samples or studies conducted in a 
single site which may limit transferability of the findings. 
Furthermore, although the characteristics of the sample 
were generally reasonably described, in order to address 
our research question, we required information about 
medication use of participants which was frequently not 
described.
Using the CASP tool, 12 (48%) studies were scored 
as high value and the remaining 13 (52%) studies as 
moderate value. For 5/13 (38%) studies scored as 
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta- Analyses diagram.
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Table 2 Quality appraisal
Author
CASP tool question*
Comments†1 2 3 4 5 6 7 8 9 10
Group 1: views of osteoporosis
  Besser et al23 ✓ ✓ ✓ p ✓ ✓ p ✓ Moderate Small sample, no mention of data saturation, limited to 
‘psychological’ factors affecting adherence (discounting other 
factors by omission) and some use of normative statements
  Jaglal et al29 ✓ ✓ ✓ ✓ ✓ u ✓ ✓ ✓ Moderate Few findings relevant to our research question
  Otmar et al28 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Moderate Well conducted study, but limited findings relating to 
bisphosphonates
  Sale et al24 ✓ ✓ ✓ ✓ ✓ u ✓ ✓ ✓ High
  Sale et al25 ✓ ✓ ✓ p ✓ u ✓ p ✓ Moderate Small single site study, although data saturation reached. 
Language does not always appear to match approach (eg, 
reporting patient ‘inability’ to link fractures to osteoporosis 
suggests prior normative assumptions)
  Weston et al26 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ High
Group 2: views of osteoporosis treatment
  Alami et al35 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ High
  Drew et al34 ✓ ✓ ✓ ✓ ✓ u ✓ ✓ ✓ High
  Feldstein et al16) ✓ ✓ ✓ ✓ ✓ u ✓ ✓ ✓ High
  Guzman- Clark 
et al36
✓ ✓ ✓ ✓ ✓ u ✓ u ✓ Moderate Only partially relevant for our review given the focus on a 
specific population (glucocorticoid- induced osteoporosis)
  Merle et al32 ✓ ✓ ✓ p ✓ u ✓ u ✓ Moderate Small sample (although data saturation reached) without 
attempt to structure to population and analysis lacks depth to 
answer our objective relating to bisphosphonate acceptability
  Merle et al33 ✓ ✓ ✓ ✓ ✓ u ✓ ✓ ✓ Moderate Limited information relevant to our research question in view of 
general focus on osteoporosis
  Iversen et al39 ✓ ✓ ✓ p ✓ ✓ p ✓ Moderate Single centre study, although data saturation reached, limited 
information on coding/analysis and no discussion of findings 
with relevance to wider literature
  Lau et al37 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ High
  Salter et al38 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ High
  Hansen et al27 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ High
  Mazor et al40 ✓ ✓ ✓ ✓ ✓ u ✓ u ✓ Moderate Good relevance, single site. Descriptive approach without 
critical reflexivity or discussion of prior assumptions
  Sale et al44 ✓ ✓ ✓ ✓ ✓ u ✓ ✓ ✓ High
  Swart et al42 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ High
  Scoville et al43 ✓ ✓ ✓ ✓ ✓ u ✓ ✓ ✓ Moderate Well conducted videographic study, but data coded against 
deductive categories of reasons to reject treatment, so limited 
potential to inform our objective about acceptability
  Wozniak et al41 ✓ ✓ ✓ ✓ ✓ u ✓ ✓ ✓ High
  Sturrock et al46 ✓ ✓ ✓ ✓ ✓ u ✓ ✓ ✓ High
  Sturrock et al45 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Moderate Aim only partially relevant to study question
Group 3: non- specific osteoporosis issues
  Ailabouni et al30 ✓ ✓ ✓ p ✓ ✓ ✓ ✓ ✓ Moderate Relatively small (10 respondents) study, although data 
saturation reached. Only partially relevant for current 
review with brief coverage of GPs views on discontinuing 
bisphosphonates in light of multimorbidities
  Sippli et al31 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Moderate Limited findings related to our research question
Continued
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moderate in value, this was due to methodological issues, 
and, for 8/13 (62%) studies this was because the focus of 
the paper was less relevant to our research question.
Fifteen individual subthemes were identified which 
mapped to the seven domains of the TFA. Key findings 
relating to ethicality related to conflict between bisphos-
phonates and participants’ values and were usually 
discussed as part of sense making. For this reason, issues 
relating to ‘ethicality’ were considered as part of ‘inter-
vention coherence’, leaving six main themes, as shown 
schematically in figure 2. Although it was possible to 
distinguish between two temporal perspectives, related 
to anticipated and experienced acceptability within most 
domains (with the exception of self- efficacy) the majority 
of anticipated acceptability findings related to interven-
tion coherence.
The findings of the review are discussed later with 
GRADE- CERQual ratings of confidence in table 3 and 
illustrative key findings for each theme/subtheme shown 
in online supplemental file 2. Subthemes are identified in 
the text in italics.
Intervention coherence (high confidence)
Both before starting, and during treatment, patients 
considered the perceived need or necessity for bisphos-
phonates based on their views of osteoporosis, including 
its seriousness and controllability, symptoms and their 
perception of their own health. Perceived need was weighed 
up against concerns about medication, including suspicion 
of drugs in general and specific concerns about bisphos-
phonate safety, by both patients and HCPs. HCPs some-
times used principles of ethicality to support perceptions 
of low necessity and their reluctance to prescribe. The 
decision process of balancing necessity against concerns, 
was influenced by the doctor–patient relationship and 
wider societal influences including friends, family and the 
general media. This process influenced whether HCPs 
reported recommending bisphosphonates. For patients, 
the decision process could be explicit or tacit, was revis-
ited over time and influenced both whether they initiated 
treatment and subsequently adhered.
Perceived effectiveness (high confidence)
Both patients and HCPs expressed doubt or uncer-
tainty about the mechanism of effectiveness of bisphospho-
nates and expressed a range of treatment expectations 
including strengthening bone—improving bone density, 
preventing worsening of osteoporosis—maintaining 
bone density and/or total fracture prevention. Patients 
wanted proof or evidence of effectiveness through more 
structured monitoring and follow- up, and were disincentiv-
ised to continue treatment in the absence of evidence of 
perceived effectiveness.
Author
CASP tool question*
Comments†1 2 3 4 5 6 7 8 9 10
*Critical Appraisal Skills Programme (CASP) quality assessment questions: (1) was there a clear statement of the aims of the research?; 
(2) is a qualitative methodology appropriate?; (3) was the research design appropriate to address the aims of the research?; (4) was the 
recruitment strategy appropriate to the aims of the research?; (5) was the data collected in a way that addressed the research issue?; (6) has 
the relationship between researcher and participants been adequately considered?; (7) have ethical issues been taken into consideration?; (8) 
was the data analysis sufficiently rigorous?; (9) is there a clear statement of findings?; (10) value of study and relevance to review objectives. 
✓=yes, u=unsure, p=partial, blank=no.
†Comments only made for those ranked moderate or low.
GP, general practitioner.
Table 2 Continued
Figure 2 Identified themes and subthemes mapped to the theoretical framework of acceptability (TFA). HCP, healthcare 
professional.
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Self-efficacy (high confidence)
Measures to help patients integrate medication taking 
into daily routines (supporting routinisation), and the 
provision of information and support, enhanced their 
feeling of having control over their health and confi-
dence to adhere to bisphosphonates. Clinician reported 
barriers to supporting adherence related to perceptions 
of their knowledge and attitudes, with several knowledge 
gaps and uncertainties reported, and the perception that 
osteoporosis was not a priority. Finally, service level barriers 
which impaired clinicians’ self- efficacy in recommending 
and managing patients on bisphosphonates, included 
uncertainty about professional roles and responsibilities, 
capacity, access to intravenous drugs and communication 
and IT systems.
Affective attitudes (moderate confidence)
The emotions elicited by bisphosphonates were closely 
related to intervention coherence. Bisphosphonates were 
associated predominantly with negative emotions of fear 
(of side effects) and annoyance (with special instruc-
tions); however, positive emotions of reassurance and 
hope were noted in two studies, linked to the anticipated 
protection that bisphosphonates could incur.
Burden (moderate confidence)
The burden or effort of oral bisphosphonates was 
described mostly relating to the special instructions to take 
oral bisphosphonates or experienced side effects, although 
costs incurred were also a potential source of burden. 
Only one study included the experience of a patient on 
an intravenous bisphosphonate, this patient described 
low treatment burden as she only had to go once a year, 
and felt no side effects.31
Opportunity costs (low confidence)
There were few descriptions of ‘benefits, profits, or values’ 
being given up to take bisphosphonates. However, circum-
stances where competing priorities challenged adherence 
or initiation of bisphosphonates were described relating 
to comorbid conditions. The presence of comorbid condi-
tions was described as resulting in less time to support 
discussion about bisphosphonates in consultations and, 
result in recommendation of, and adherence to, bisphos-
phonates being given relative low priority.
DISCUSSION
This systematic review has used the lens of acceptability 
to understand perceptions of bisphosphonates and the 
problem of poor adherence. We have identified, with high 
confidence, how patients and HCPs make sense (coher-
ence) of bisphosphonates by balancing perceptions of 
need against concerns, how uncertainty prevails about 
perceived effectiveness of bisphosphonates and how a 
number of individual and service factors have potential 
to increase self- efficacy in recommending and adhering 
to bisphosphonates. We identified with moderate 
confidence, that bisphosphonate taking induces fear, but 
has the potential to engender reassurance, and that both 
the side effects and special instructions for taking oral 
bisphosphonates can be a source of treatment burden. 
Finally, we identified with low confidence that multimor-
bidity plays a role in people’s perception of bisphospho-
nate acceptability.
To our knowledge, this is the first use of the TFA, orig-
inally developed to evaluate acceptability of complex 
interventions, to evaluate the acceptability of medication. 
We explored the utility of the TFA from two perspectives, 
as an explanatory model for both patient and clinician 
acceptability and engagement. The TFA was useful for 
understanding and combining patient and clinician view-
points; however, there was considerable overlap between 
domains; perceived efficacy, affective attitudes and self- 
efficacy beliefs are all likely to impinge on sense- making, 
or intervention coherence. The TFA alone does not 
provide a comprehensive framework for understanding 
patient acceptability or engagement with medicines, 
and of course it was not intended to do so. The sense- 
making aspect of the framework appeared pivotal, and 
the explanatory value of the framework was enhanced 
by the incorporation of the NCF to operationalise key 
engagement related beliefs. In the context of bisphospho-
nates, concern and associated fears predominate among 
patients, and perceived need may be underestimated if 
the consequences of osteoporosis and fragility fractures 
are not explained. In our findings, sense making was 
dynamic. Patients re- evaluated perceptions of bisphospho-
nates over time, expressing uncertainty relating to what 
represents successful treatment and citing perceived lack 
of effectiveness being cited as reason to discontinue. This 
is likely to be a particular problem for bisphosphonates, as 
opposed to other drugs commonly taken for prevention 
such as statins and antihypertensive, where measures of 
feedback and effectiveness are more readily available.
The UK National Institute for Health and Care Excel-
lence (NICE) guidelines for medicines adherence 
emphasises the need to take into account perceptions 
(eg, necessity beliefs and concerns) and practicalities (eg, 
capability and resources) that will affect individuals’ moti-
vation and ability to start and continue with treatment.47 
However, interventions designed to improve bisphos-
phonate adherence are often designed to ‘educate’ 
or persuade the patient of importance and are often 
not targeted to eliciting or addressing health beliefs, 
or informed by underpinning mechanisms of change.3 
There is therefore a need to ensure that any further 
design of interventions—to promote bisphosphonate 
adherence—draws on more comprehensive theoretical 
models of patient engagement with health conditions and 
medicines such as the Extended Common Sense Model.48 
This model situates individual’s perceptions about drugs, 
and practical issues related to capability, in the context of 
illness and treatment representations.
Specifically, our findings suggest a need for clinicians to 
support patients to understand the need for treatment, to 
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allay concerns where possible and to define what consti-
tutes successful bisphosphonate treatment. Furthermore, 
clinicians need to support patients evaluate the advan-
tages and disadvantages over time, given the dynamic 
nature of these decision processes.48
It is clear from our findings that clinicians also have 
necessity- concern dilemmas relating to bisphospho-
nates. A number of studies reported clinicians them-
selves perceiving low patient need, high concerns and 
perceptions treatment was not practical. This is perhaps 
in contrast with a previous quantitative study in asthma 
which demonstrated that clinicians held stronger positive 
beliefs about medicines than patients.49 It is unclear to 
what extent the perceptions in our findings were gener-
alisations or applied in specific circumstances, or to what 
extent these views were negotiated on an individual basis 
in discussion with patients. Problems may arise in the 
consultation if clinicians assume patients share their views 
and then may be less likely to explore patient percep-
tions of need or concerns. Furthermore, the limitations 
of interviewing HCPs are well documented; the accounts 
presented in an interview may not represent clinician 
underlying beliefs or behaviours meaning that observa-
tional methods may be more appropriate to fully under-
stand clinical decisional making.50 Given the clinician has 
a pivotal role in sense making, interventions are also likely 
needed to address clinician knowledge, attitudes and 
beliefs. By including the views of clinicians and managers 
we have also identified a range of service level barriers 
to promoting bisphosphonate adherence relating to lack 
of clarity about professional roles, both across primary 
and secondary care, and within primary care, use of IT 
systems and access to intravenous treatments.
A strength of this review is the comprehensive search, 
use of underpinning theoretical framework, the inclu-
sion of clinician views in addition to patients, and the use 
of the GRADE- CERQual to give confidence in our find-
ings which has facilitated a clear identification of where 
further research is needed. Areas where we have identi-
fied moderate or low confidence are in need of further 
research and specifically relate to the influence of multi-
morbidity on sense making, burden and self- efficacy in 
bisphosphonate users, the extent to which intravenous 
bisphosphonates may overcome issues related to treatment 
burden and self- efficacy, and the impact of bisphospho-
nates on affective attitudes and emotions. Furthermore, 
we have identified gaps in our understanding of how 
clinicians make decisions in practice, and how views of 
bisphosphonates may be influenced by gender. Given 
that many osteoporosis drugs have a different evidence 
base and licensing arrangements in men this is an area in 
need of further study.
The main limitation of this study relates to the lack 
of clarity in many of the included studies in the results 
sections about which osteoporosis treatments or bisphos-
phonates were being referred to, meaning that in some 
cases we may have over- interpreted findings relating to 
bisphosphonates that were about other osteoporosis 
drugs. However, all of our review findings were identi-
fied from comparison of data from several studies, and 
as bisphosphonates represent the mainstay of osteopo-
rosis treatment, we consider that over- interpretation is 
unlikely. As there was frequently little detail about medi-
cation participants were taking or referring to, it is also 
possible that we have missed relevant studies. The views 
of men were under- represented; although 8/18 studies 
included men, men represented less than 20% of the total 
patient population in the included studies. It is important 
for future studies to include males and specific popula-
tions such as those with glucocorticoid- induced osteo-
porosis who are likely to have different experiences and 
needs.51 Only two studies reported the views of managers 
but unfortunately neither of these studies distinguished 
professional roles in the presentation of results, so a 
further need exists to explore perceptions of this group, 
and perceptions of payors and academics. Finally, 
although the population from which each study sampled 
was reasonably well described, it was not always possible 
to appreciate if the setting was primary or secondary care; 
the majority of studies appeared to recruit from primary 
care which may explain the lack of findings related to 
intravenous bisphosphonates and limit the transferability 
of our findings to non- primary care settings.
CONCLUSIONS
In summary, using the lens of acceptability, we have iden-
tified the factors that influence how patients and clini-
cians make sense of bisphosphonates, described the 
experience of bisphosphonate taking in terms of burden 
and factors that both facilitate and hinder confidence in 
taking, and prescribing and monitoring bisphosphonates. 
Our findings demonstrate the need for a theoretically 
informed, whole- system approach’ to enable clinicians 
and patients to get the best from bisphosphonate treat-
ment. Patients need comprehensive support that takes 
account of the perceptions (eg, treatment necessity 
beliefs and concerns) and practicalities (eg, capability 
and resources) that influence their motivation and ability 
to start and continue with treatment. Clinicians need to 
moderate patient expectations and clarify what consti-
tutes bisphosphonate treatment success. Finally, further 
research is needed to explore perspectives of managers, 
patients receiving intravenous bisphosphonates, men 
receiving bisphosphonates and the use of bisphospho-
nates in the context of multimorbidity.
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